全球视野下的PROTAC：第19届圣地亚哥生物制药年会分享

演讲者信息
About Presenter

戴学东博士

Dr. Xuedong Dai

ExecutiveVP and Head of IDSU (International Discovery Service Unit) at Medicilon,obtained his Ph.D. in organic chemistry at MIT. He is a senior-level expertwith over 20 years of experience focusing on small molecule drug discovery anddevelopment in CNS, infectious disease, and oncology therapy areas. He has deepunderstanding and practical knowledge of drug discovery process, including leadidentification, optimization, and development of high quality clinicalcandidate molecules. Prior to Medicilon, Dr. Dai worked at Janssen, HDBiosciences, GSK, and Xenoportwith a demonstrated successful track record ofprogram leadership and made significant contributions to medicinal chemistryprograms that led to the marketed drug Horizant?/Regnite? and several otherclinical candidates (JNJ-75276617, arbaclofen placarbil, XP21279, and XP23829).

yl23455永利国际研发效劳部
Medicilon International Discovery Service Unit

The mission of Medicilon International Discovery Service Unit is to provide high quality, efficient and cost-effective synthetic chemistry, drug design, and new drug candidate compound services to global pharmaceutical companies.  We are stride to meet the research and development needs of the clients in various chemical fields of pre-clinical new drug research, shorten the cycle of drug R&D, and reduce the cost of drug R&D.

Medicilon International Discovery Service Unit has a management team and lab personnel with a rich background of studying abroad, a world-leading synthesis and analysis laboratory with installed state-of-the-art instruments and equipment.  In order to provide clients with better services, the International Discovery Service Unit keeps up with new developments and new technologies in drug design and synthesis, such as artificial intelligence/machine learning (AI/ML), proteolysis targeting chimera (PROTAC), antibody-drug conjugates (ADC), direct functionalization of inert carbon-hydrogen bonds, photoredox reactions, and flow chemistry, etc.

yl23455永利聚会报告
Medicilon conference presentation

以上为部分PPT分享

PROTAC手艺平台
Medicilon PROTAC Platform

Proteolysis Targeting Chimeras (PROTACs) are interesting biology as achemical knock-down approach in a fast and reversible way. Medicilon has established a wide range of popular target proteins withhigh affinity small molecules and small molecule fragment compound libraries, awide range of E3 ligases, and high affinity small molecules and small moleculefragments. We offer these services in any format you like;we can only do the chemical synthesis part for you, only the in vitro and/or invivo part, or we can offer a fully combined package.